A review on recent advancements in ophthalmology devices: Currently in market and under clinical trials

Nagaraj, Rajini; Bijukumar, Divya; Mathew, Benjamin; Scott, Evan A.; Mathew, Mathew T.

doi:10.1016/j.jddst.2019.04.038

Cited by 12 publications

(12 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Nanospheres are spherical nanovesicles with a size ranging from 10 to 200 nm and made of biodegradable polymers that protect the drug from degradation. In nanospheres, the drug is entrapped inside the polymer or attached to the surface of the particles and capable of sustained drug release [ 49 , 76 , 81 ]. Nanocapsules, with a size ranging from 10 to 200 nm, are composed of a hydrophilic or lipophilic core or cavity surrounded by a polymeric membrane called the capsule.…”

Section: Therapeutic Approach: Points To Considermentioning

confidence: 99%

“… Nanocapsules, with a size ranging from 10 to 200 nm, are composed of a hydrophilic or lipophilic core or cavity surrounded by a polymeric membrane called the capsule. Nanocapsule, encapsulates relatively large amounts of drugs in the core, and present a more sustained release of the drug [ 76 , 82 ]. Liposomes are spherical amphipathic vesicles made of a naturally biocompatible phospholipid bilayer, resembling a cellular membrane that surrounds an aqueous core.…”

Section: Therapeutic Approach: Points To Considermentioning

confidence: 99%

See 1 more Smart Citation

Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision

et al. 2022

View full text Add to dashboard Cite

Photoreceptors (PRs), as the most abundant and light-sensing cells of the neuroretina, are responsible for converting light into electrical signals that can be interpreted by the brain. PR degeneration, including morphological and functional impairment of these cells, causes significant diminution of the retina’s ability to detect light, with consequent loss of vision. Recent findings in ocular regenerative medicine have opened promising avenues to apply neuroprotective therapy, gene therapy, cell replacement therapy, and visual prostheses to the challenge of restoring vision. However, successful visual restoration in the clinical setting requires application of these therapeutic approaches at the appropriate stage of the retinal degeneration. In this review, firstly, we discuss the mechanisms of PR degeneration by focusing on the molecular mechanisms underlying cell death. Subsequently, innovations, recent developments, and promising treatments based on the stage of disorder progression are further explored. Then, the challenges to be addressed before implementation of these therapies in clinical practice are considered. Finally, potential solutions to overcome the current limitations of this growing research area are suggested. Overall, the majority of current treatment modalities are still at an early stage of development and require extensive additional studies, both pre-clinical and clinical, before full restoration of visual function in PR degeneration diseases can be realized. Graphical Abstract

show abstract

Section: Therapeutic Approach: Points To Considermentioning

confidence: 99%

Section: Therapeutic Approach: Points To Considermentioning

confidence: 99%

Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Based on the investigations conducted by the World Health Organization (WHO) in 2015, almost 217 million people aged 18 years or older globally are suffering from various ocular disorders that could lead to vision impairment and finally cause permanent blindness [ 1 , 2 ]. In the last ten years, immense preclinical and clinical studies have been performed for the development of therapeutics for different ophthalmic disorders, for example, diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, cataracts, and uveitis [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

2022

View full text Add to dashboard Cite

Ocular drug delivery is one of the most challenging endeavors among the various available drug delivery systems. Despite having suitable drugs for the treatment of ophthalmic disease, we have not yet succeeded in achieving a proper drug delivery approach with the least adverse effects. Nanotechnology offers great opportunities to overwhelm the restrictions of common ocular delivery systems, including low therapeutic effects and adverse effects because of invasive surgery or systemic exposure. The present review is dedicated to highlighting and updating the recent achievements of nano-based technologies for ocular disease diagnosis and treatment. While further effort remains, the progress illustrated here might pave the way to new and very useful ocular nanomedicines.

show abstract

“…Worldwide, the third leading cause of blindness is retinal degenerative diseases caused by photoreceptor loss, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Efforts to treat blind patients with AMD and RP go from the regulation of vitamins, to the development of novel experimental strategies like stem-cell based therapy, gene therapy, transplantation of lost retinal tissue, and visual prostheses [1][2][3] . To restore the lost function of photoreceptors while using the remaining healthy network in the retina, visual prostheses that stimulate the retina electrically are used.…”

mentioning

confidence: 99%

“…(ii) As illustrated in Fig. 1a, the dimensions of flexible BiMEAs have a reduced cross-section compared to Si-BiMEAs from 1500-2500 µm 2 (widths of 60 or 100 µm and a thickness of 25 µm) to 150-700 µm 2 (widths of 50 or 100 µm and a thickness of between 3 and 7 µm), thereby minimizing the cross-sectional footprint of the shanks 3.5-10 times. (iii) Due to the known stiffness of Si (hundreds of GPa), biocompatible and flexible materials, such as polyimide (PI) and parylene-C (PaC), with a Young's modulus lower than tens of GPa [13][14][15] were selected for the development of flexible intraretinal probes.…”

mentioning

confidence: 99%

Development and in vitro validation of flexible intraretinal probes

Montes

Gehlen

Ingebrandt

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The efforts to improve the treatment efficacy in blind patients with retinal degenerative diseases would greatly benefit from retinal activity feedback, which is lacking in current retinal implants. While the door for a bidirectional communication device that stimulates and records intraretinally has been opened by the recent use of silicon-based penetrating probes, the biological impact induced by the insertion of such rigid devices is still unknown. Here, we developed for the first time, flexible intraretinal probes and validated in vitro the acute biological insertion impact in mouse retinae compared to standard silicon-based probes. Our results show that probes based on flexible materials, such as polyimide and parylene-C, in combination with a narrow shank design 50 µm wide and 7 µm thick, and the use of insertion speeds as high as 187.5 µm/s will successfully penetrate the retina, reduce the footprint of the insertion to roughly 2 times the cross-section of the probe, and induce low dead cell counts, while keeping the vitality of the tissue and recording the neural activity at different depths.

show abstract

A review on recent advancements in ophthalmology devices: Currently in market and under clinical trials

Cited by 12 publications

References 96 publications

Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision

Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

Development and in vitro validation of flexible intraretinal probes

Contact Info

Product

Resources

About